Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 3
2007 4
2008 1
2009 2
2010 1
2011 7
2012 5
2013 3
2014 5
2015 8
2016 9
2017 10
2018 10
2019 8
2020 9
2021 16
2022 24
2023 22
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

140 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean tang qi yu (6 results)?
New Insights in the Treatment of SAPHO Syndrome and Medication Recommendations.
Cheng W, Li F, Tian J, Xie X, Chen JW, Peng XF, Tang Q, Ge Y. Cheng W, et al. Among authors: tang q. J Inflamm Res. 2022 Apr 13;15:2365-2380. doi: 10.2147/JIR.S353539. eCollection 2022. J Inflamm Res. 2022. PMID: 35444448 Free PMC article. Review.
This article reviews the application of biologics and other treatments based on the therapeutic target and the size of molecules in SAPHO syndrome. We found that drugs, especially biologics, have different effects on bone, joint, and skin damage. ...
This article reviews the application of biologics and other treatments based on the therapeutic target and the size of molecules in S …
Patient-Derived Upper Tract Urothelial Carcinoma Organoids as a Platform for Drug Screening.
Li Z, Xu H, Gong Y, Chen W, Zhan Y, Yu L, Sun Y, Li A, He S, Guan B, Wu Y, Xiong G, Fang D, He Y, Tang Q, Yao L, Hu Z, Mei H, He Z, Cai Z, Guo Y, Li X, Zhou L, Huang W. Li Z, et al. Among authors: tang q. Adv Sci (Weinh). 2022 Feb;9(4):e2103999. doi: 10.1002/advs.202103999. Epub 2021 Dec 16. Adv Sci (Weinh). 2022. PMID: 34914855 Free PMC article.
Expanding individualized therapeutic options via genoproteomics.
Zhan D, Zheng N, Zhao B, Cheng F, Tang Q, Liu X, Wang J, Wang Y, Liu H, Li X, Su J, Zhong X, Bu Q, Cheng Y, Wang Y, Qin J. Zhan D, et al. Among authors: tang q. Cancer Lett. 2023 Apr 28;560:216123. doi: 10.1016/j.canlet.2023.216123. Epub 2023 Mar 11. Cancer Lett. 2023. PMID: 36907503 Free article.
RNAi-based drug design: considerations and future directions.
Tang Q, Khvorova A. Tang Q, et al. Nat Rev Drug Discov. 2024 May;23(5):341-364. doi: 10.1038/s41573-024-00912-9. Epub 2024 Apr 3. Nat Rev Drug Discov. 2024. PMID: 38570694 Review.
Synthetic siRNAs that trigger RNAi have the potential to specifically silence virtually any therapeutic target with unprecedented potency and durability. Bringing this innovative class of medicines to patients, however, has been riddled with substantial challenges, with de …
Synthetic siRNAs that trigger RNAi have the potential to specifically silence virtually any therapeutic target with unprecedented pot …
Plant-derived exosomal nanoparticles: potential therapeutic for inflammatory bowel disease.
Li DF, Tang Q, Yang MF, Xu HM, Zhu MZ, Zhang Y, Tian CM, Nie YQ, Wang JY, Liang YJ, Wang LS, Yao J. Li DF, et al. Among authors: tang q. Nanoscale Adv. 2023 Jun 23;5(14):3575-3588. doi: 10.1039/d3na00093a. eCollection 2023 Jul 11. Nanoscale Adv. 2023. PMID: 37441251 Free PMC article. Review.
However, currently available disease-modifying anti-IBD drugs exhibit limited efficacy in IBD therapy. Furthermore, existing therapeutic approaches provide only partial relief from IBD symptoms and are associated with certain side effects. ...In the present study, we provi …
However, currently available disease-modifying anti-IBD drugs exhibit limited efficacy in IBD therapy. Furthermore, existing therapeutic …
Rational design of a JAK1-selective siRNA inhibitor for the modulation of autoimmunity in the skin.
Tang Q, Fakih HH, Zain Ui Abideen M, Hildebrand SR, Afshari K, Gross KY, Sousa J, Maebius AS, Bartholdy C, Søgaard PP, Jackerott M, Hariharan V, Summers A, Fan X, Okamura K, Monopoli KR, Cooper DA, Echeverria D, Bramato B, McHugh N, Furgal RC, Dresser K, Winter SJ, Biscans A, Chuprin J, Haddadi NS, Sherman S, Yıldız-Altay Ü, Rashighi M, Richmond JM, Bouix-Peter C, Blanchard C, Clauss A, Alterman JF, Khvorova A, Harris JE. Tang Q, et al. Nat Commun. 2023 Nov 4;14(1):7099. doi: 10.1038/s41467-023-42714-4. Nat Commun. 2023. PMID: 37925520 Free PMC article.
This work establishes a path toward siRNA treatments as a new class of therapeutic modality for inflammatory and autoimmune skin diseases....
This work establishes a path toward siRNA treatments as a new class of therapeutic modality for inflammatory and autoimmune skin dise …
Therapeutic applications of adipose-derived stromal vascular fractions in osteoarthritis.
Tang Q, Zhao XS, Guo A, Cui RT, Song HL, Qi ZY, Pan Y, Yang Y, Zhang FF, Jin L. Tang Q, et al. World J Stem Cells. 2022 Oct 26;14(10):744-755. doi: 10.4252/wjsc.v14.i10.744. World J Stem Cells. 2022. PMID: 36337155 Free PMC article. Review.
According to previous studies, it contains a large number of mesenchymal stem cells, which have been used to treat OA with good therapeutic results. This safe, simple, and effective therapy is expected to be applied and promoted in the future. In this paper, the detailed p …
According to previous studies, it contains a large number of mesenchymal stem cells, which have been used to treat OA with good therapeut …
The Role of Sphingolipid Metabolism in Bone Remodeling.
Qi T, Li L, Weidong T. Qi T, et al. Front Cell Dev Biol. 2021 Nov 29;9:752540. doi: 10.3389/fcell.2021.752540. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34912800 Free PMC article. Review.
This review also shows agonists and antagonists of S1P as possible therapeutic options and opportunities on bone diseases....
This review also shows agonists and antagonists of S1P as possible therapeutic options and opportunities on bone diseases....
Hepatic macrophage mediated immune response in liver steatosis driven carcinogenesis.
Tu T, Alba MM, Datta AA, Hong H, Hua B, Jia Y, Khan J, Nguyen P, Niu X, Pammidimukkala P, Slarve I, Tang Q, Xu C, Zhou Y, Stiles BL. Tu T, et al. Among authors: tang q. Front Oncol. 2022 Oct 5;12:958696. doi: 10.3389/fonc.2022.958696. eCollection 2022. Front Oncol. 2022. PMID: 36276076 Free PMC article. Review.
Engineering c-Met-CAR NK-92 cells as a promising therapeutic candidate for lung adenocarcinoma.
Peng Y, Zhang W, Chen Y, Zhang L, Shen H, Wang Z, Tian S, Yang X, Cui D, He Y, Chang X, Feng Z, Tang Q, Mao Y. Peng Y, et al. Among authors: tang q. Pharmacol Res. 2023 Feb;188:106656. doi: 10.1016/j.phrs.2023.106656. Epub 2023 Jan 11. Pharmacol Res. 2023. PMID: 36640859 Free article.
Mesenchymal-epithelial transition factor (C-Met) has been acknowledged as a significant therapeutic target for treating lung adenocarcinoma (LUAD). However, the potential application of chimeric antigen receptors (CAR)-modified natural killer (NK) cells targeting c-Met in …
Mesenchymal-epithelial transition factor (C-Met) has been acknowledged as a significant therapeutic target for treating lung adenocar …
140 results